B19 parvovirus is pathogenic in humans, causing the common childhood exanthem fifth disease and bone-marrow failure, both acute (transient aplastic crisis of hemolysis) and chronic (pure erythrocyte aplasia in immunodeficiency). The virus is tropic for a human red cell progenitor cell, and failure to culture B19 in a cell line has limited its clinical study. We cotransfected the right half ofthe cloned B19 genome and a minigene derived from the human dihydrofolate reductase gene (DHFR) into dhfr-Chinese hamster ovary cells and screened selected clones by RNA analysis; after amplification in methotrexate, clones were tested for capsid protein expression. A cell line, designated 3-11-5, stably expressed nearly full-length transcripts for the two capsid proteins. These cells produced the major and minor structural protein species in natural proportions that self-assembled into virion capsids. Capsids from 3-11-5 cells could be separated from virions by sucrose gradient sedimentation and had the density on cesium chloride isopycnic sedimentation of empty parvovirus capsids. Capsid protein was present in both nuclei and cytoplasm on immunofluorescence study but fractionated with the cytosol on purification.
than virion production by infected bone-marrow cells, 1000-2000 capsids per cell, but cell growth was not diminished by capsid production. This cell line will be useful in developing practical assays for B19 parvovirus antibody and a vaccine for the virus, as well as potentially serving as a packaging cell line for gene therapy.
B19 parvovirus causes several human diseases (1) . In normal children, virus infection leads to fifth disease, a common, measles-like rash illness (2) . Adults with fifth disease usually have inflammatory joint symptoms, which may persist in a rheumatoid arthritis-like disease. In persons with underlying hemolysis, B19 causes transient aplastic crisis (3) , and in patients with underlying immunodeficiency, persistent infection leads to chronic pure red cell aplasia (4, 5) . Fetal infection can result in nonimmune hydrops fetalis and possibly spontaneous abortion early in pregnancy (6) . However, the full spectrum of illness due to parvovirus infection is unknown. The virus has very limited tropism, infecting erythroid progenitor cells, for which it is toxic (7). B19 parvovirus has been shown to replicate only in explants of human erythroid bone marrow (8) . The few research laboratories that test for virus infection have been forced to rely for antigen on very small quantities of sera known to contain virus.
The fastidious behavior of B19 parvovirus led us to develop a productive cell culture system by using genetic engineering techniques. Molecular analysis of infected bone-marrow cultures showed that the genomic organization of B19 parvovirus resembled that of other Parvoviridae, with two capsid proteins encoded by overlapping transcripts that were encoded by the right side of the genome (9, 10 ). An important early observation was that expression of the left side of the genome was associated with apparent lethality, suggesting that the nonstructural protein of B19 parvovirus was cytotoxic (11) . Finally, we used a dihydrofolate reductase minigene, which served to select cells containing transfected genes, to amplify the gene number, and to increase protein expression.
MATERIALS AND METHODS
Cell Culture. The dhfr-Chinese hamster ovary (CHO) cell line DG-21 was grown in Iscove's modified Eagle's medium containing 10o fetal calf serum, 0.1 mM glycine, 0.1 mM hypoxanthine, 0.016 mM thymidine (collectively, GHT+ medium), nonessential amino acids, and antibiotics at 37°C and 95% humidity (12) . The 3-11-5 cell line was maintained in GHT-medium with added 10 ,uM methotrexate (Lederle Laboratories, Pearl River, NY). Human bone-marrow cells, obtained from normal donors or patients with sickle cell disease, were obtained with informed consent under approved protocol of the National Heart, Lung, and Blood Institute institutional review board. Mononuclear cells were cultured in Iscove's modification of Dulbecco's medium with 20% fetal calf serum and recombinant human erythropoietin at 1 unit/ml (Amgen Biologicals) and infected with parvovirus-containing serum as described (13) .
Plasmid Construction and Transfection. Plasmids were constructed by using standard methods (14) and information derived from cloning (15) and sequencing (16) ofthe virus and its expression in human marrow cells (11) . The capsid expression vector pCP94 (Fig. 1A) pepstatin A at 1 ug/ml; leupeptin hemisulfate at 5 pug/ml) were precipitated with high-titer convalescent-phase human antiserum and subjected to 8% PAGE as described (17) . Immunoblot was done with unlabeled cell lysates and human immune serum as described (17) . For (1989) pOlyA expression when screened by immunofluorescence; because of its very high intensity of specific fluorescence, a clone termed 3-11-5 was chosen for further characterization.
For Southern analysis, DNA from the 3-11-5 cell line was digested with the enzyme Hpa I; the two enzyme sites within the transfected parvovirus capsid protein sequence of 3.4 kb would result in an expected excised fragment of 1.7 kb (Fig.  2 Lower). After hybridization with a radioactively labeled, full-length B19 parvovirus probe, DNA from 3-11-5 cells showed a single fragment of the expected 1.7 kb, which was greatly amplified (>10-fold) by growth in 10 AM methotrexate ( Fig. 2 Upper Left) . The presence of a heterogeneous pattern of higher-molecular-weight DNA fragments that hybridized with the parvovirus probe suggested random integration of the vector as expected.
On Northern analysis, two discrete B19 transcripts were present, of slightly smaller dimension than the capsid RNA species present in infected bone-marrow cells. This result was anticipated because a region upstream of the coding sequences of the structural proteins, including the normal splice acceptor sites at nt 1908 and 2028 (9), was deleted during plasmid construction (Fig. 2 Lower). The number of parvovirus RNA transcripts also was greatly increased after exposure to methotrexate ( 
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RNA probably represents hybridization with abundant cellular ribosomal RNA, which behaves anomalously on electrophoresis due to its very high concentration; this common artifact disappears after purification of polyadenylylated RNA.) In comparison to either the parental CHO cell line or transformed CHO cells, the growth of 3-11-5 cells was normal (data not shown). Cells have retained amplified B19 DNA after -50 serial passages.
Expression of B19 Protein. Both the major 58-kDa and minor 83-kDa capsid species were detected in lysates of 3-11-5 cells (Fig. 3) . The 58-kDa capsid protein was =6-fold more abundant than the 83-kDa protein, comparable to the ratio in infected erythroid cells of 10-20:1. As determined by immunoblot of lysates of cells from mature cultures, accumulation ofcapsid proteins in the cell line was superior to that from infected normal bone-marrow culture, although not as great as seen after infection of predominantly erythroid cells in marrow from a patient with sickle cell disease (Fig. 3A) . By comparison with human serum from infected patients, the genome copy number of an average 3-11-5 cell was calculated to be 1-2 x 103, in comparison with 8 x 103 copies in an average infected erythroid cell. However, kinetic analysis of capsid production after pulse labeling of cultures showed that 58-kDa protein synthesis was 30-to 40-fold higher in 3-11-5 cells than in total normal bone-marrow cells at the height of virus protein production (Fig. 3B ). By immunofluorescence with either a specific monoclonal antibody or convalescentphase serum, B19 protein was detected in both nuclei and cytoplasm of virtually every 3-11-5 cell, with some cells showing characteristic localization of staining in nucleoli (Fig. 4) . However, extraction of separated nuclear and cytosol fractions resulted in the bulk ofcapsid protein appearing in the cytosol (data not shown), possibly the result of leakage of proteins with swelling of the nuclear membrane. Capsid Assembly. To determine whether parvovirus protein products assembled into intact capsids, cultures of 3-11-5 cells and virus-infected erythroid bone-marrow cells were labeled with a radioactive amino acid, and virus protein was subjected to partial purification through a sucrose cushion followed by density-gradient or isopycnic sedimentation. More than 90% of the labeled capsid proteins of 3-11-5 cells were present in the pellet after centrifugation through a dense sucrose cushion (data not shown). Labeled virus from cultures could be separated from intact virus present in marrow cultures by sucrose density-gradient sedimentation (Fig. SA) .
In CsCl, [35Slmethionine-labeled capsid protein sedimented with the expected density of empty parvovirus capsids (1.31 g/ml) compared with intact virions from infected cultures (1.42 g/ml) (Fig. SB) . Particles of the appropriate appearance and dimension for parvovirus were detected in the peak fraction by transmission electron microscopic study of negatively stained preparations (Fig. 5B Inset) .
Capsids (20) . More recently, expression of murine parvovirus structural proteins by bovine papillomavirus-minute virus of mice chimera also led to empty capsid production, but the transformed cells were genetically unstable (21) . Our results support the conclusions of other authors (19) (20) (21) that empty capsid formation may precede DNA insertion to form intact infectious virions. In our stably transformed cells, empty capsid production had no deleterious effect on cell growth, which is further evidence for the toxic role of the nonstructural protein of B19 parvovirus (10) . In addition, attempts to use cotransfection of the DHFR minigene and plasmid constructs containing the nonstructural protein gene failed to produce cells that expressed nonstructural protein. Both the nonstructural proteins and capsid proteins of parvoviruses have been shown to bind to parvovirus DNA, and both remain candidates as packaging factors for B19 parvovirus. The higher proportional production of the minor capsid protein in 3-11-5 cells compared with that in infected bone-marrow cells and the equivalent quantities of the two structural protein RNAs suggest that the relative amounts of capsid proteins in 3-11-5 cells are mainly translationally regulated by upstream AUG codons (22) .
This cell line will have great practical usefulness because it will provide an unlimited supply of antigen for the development of clinical anti-B19 parvovirus antibody assays. In preliminary experiments, crude lysates of 3-11-5 cells that had been fractionated only by-a single passage through sucrose could completely replace virus-containing serum in an ELISA for IgG and IgM directed to virus (L. Anderson, Centers for Disease Control, Atlanta, personal communication), although its use in capture immunoassays may depend on the specific monoclonal antibody used (K. E. Brown, Central Public Health Laboratory, London, personal communication). In addition to availability, the noninfectious nature of 3-11-5 lysate will also protect medical workers, who are susceptible to laboratory infection with serum samples (23) . Capsids from 3-11-5 cells are also of potential utility in development of a vaccine to prevent parvovirus infection in susceptible pregnant women and in patients with hemolytic disease, as well as in the development of specific immune serum for the treatment of patients with chronic parvovirus infection and bone-marrow suppression. Cats and dogs are successfully immunized with attenuated strains of their respective parvoviruses (24) . Development of an attenuated B19 parvovirus mutant may be not only difficult but also dangerous, because of the possibility of extension of the range of tissue tropism beyond erythroid progenitor cells (25) .
The 3-11-5 cell line should also prove useful in more basic investigations of parvovirus function. For example, it may be possible to pseudotype adenoassociated virus DNA in B19 capsids and to determine the packaging signals for B19 encapsidation. Studies of the kinetics of B19 parvovirus protein production, trafficking, and release of the cell-surface receptor for B19 parvovirus and of the specific role of nonstructural protein during cell infection will also be facilitated. Elucidation of these aspects of parvovirus biology may allow the use of this cell line for packaging of human genetic material for specific delivery to bone-marrow erythroid progenitor cells as gene therapy.
